The class action lawsuit is seeking to represent anyone who bought over-the-counter Zantac since January 1, 2010. The class action lawyers who filed the suit are hoping to get refunds for people who bought Zantac, as well as a court order to force drug-makers to stop selling Zantac or add a warning label.
To learn more about filing a Zantac lawsuit, you should contact the lawyers at Schmidt & Clark, LLP. They offer a Free Confidential Case Review.
The Zantac lawsuit accuses Sanofi and Boehringer Ingelheim of failing to warn consumers about the dangerous levels of NDMA in Zantac.
Numerous scientific studies have shown that Zantac forms NDMA when it is placed in drinking water, and that a person who takes Zantac has a 400-times more NDMA in their urine, the lawsuit claims.
Lawyers accuse drug-makers Sanofi and Boehringer Ingelheim of knowingly selling a medication with “extremely high levels of NDMA.”
NDMA is a highly-toxic carcinogenic chemical impurity that is found in the environment, but also sometimes left over from drug manufacturing. Because it is so toxic, the FDA has set a daily intake limit of 96 nanograms per day.
Unfortunately, recent testing detected more than 2,500,000 nanograms of NDMA in each 150-mg tablet of Zantac. That means some Zantac contained 26,000-times more NDMA than what the FDA considers “safe,” according to the class action lawsuit.
Even so, in a Safety Alert, the FDA said it only found “low levels” of NDMA in Zantac, and said those levels “barely exceed amounts you might expect to find in common foods.”
However, to put the level of NDMA in Zantac in perspective, dozens of recalls were recently issued for blood-pressure drugs that had a similar problem with NDMA contamination — and those drugs only had up to 17,000 nanograms of NDMA per pill, according to Bloomberg.
The zantac class action lawsuit was filed on September 13, 2019, in the U.S. District Court for the Northern District of California — In RE: Christina Garza et al vs. Sanofi-Aventis U.S. LLC; Sanofi US Services Inc.; Chattem, Inc.; and Boehringer Ingelheim Pharmaceuticals, Inc. — Case Number: 19-cv-05772.